Crizotinib: an anaplastic lymphoma kinase inhibitor (Q39720041)

14 September 2017

Crizotinib: an anaplastic lymphoma kinase inhibitor (English)

1 reference

14 September 2017

1 reference

Shirish M Gadgeel

1

1 reference

PubMed ID

21823889

14 September 2017

Gerold Bepler

series ordinal

2

1 reference

PubMed ID

21823889

14 September 2017

language of work or name

English

0 references

publication date

1 August 2011

1 reference

14 September 2017

1 reference

14 September 2017

7

1 reference

14 September 2017

8

1 reference

14 September 2017

947-953

1 reference

Anaplastic Lymphoma Kinase: role in specific tumours, and development of small molecule inhibitors for cancer therapy

14 September 2017

1 reference

Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008

21 January 2018

1 reference

Chemotherapy for lung cancer: the state of the art in 2009.

21 January 2018

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

21 January 2018

1 reference

Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia

21 January 2018

1 reference

Current and emerging pharmacological treatments for gastrointestinal stromal tumour

21 January 2018

1 reference

CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib.

21 January 2018

1 reference

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 January 2018

1 reference

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

21 January 2018

1 reference

ALK gene rearrangements: a new therapeutic target in a molecularly defined subset of non-small cell lung cancer.

21 January 2018

1 reference

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

The development of imatinib as a therapeutic agent for chronic myeloid leukemia

21 January 2018

1 reference

EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.

21 January 2018

1 reference

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

21 January 2018

1 reference

CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant

21 January 2018

1 reference

The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers

21 January 2018

1 reference

Targeting the dynamic HSP90 complex in cancer

21 January 2018

1 reference

Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer

21 January 2018

1 reference

Crizotinib in anaplastic large-cell lymphoma

21 January 2018

1 reference

Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.

21 January 2018

1 reference

Activity of crizotinib (PF02341066), a dual mesenchymal-epithelial transition (MET) and anaplastic lymphoma kinase (ALK) inhibitor, in a non-small cell lung cancer patient with de novo MET amplification

21 January 2018

1 reference

MET amplification identifies a small and aggressive subgroup of esophagogastric adenocarcinoma with evidence of responsiveness to crizotinib

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.2217/FON.11.77

1 reference

14 September 2017

1 reference

PubMed ID

21823889